United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board lifted its position in United Therapeutics Co. (NASDAQ:UTHR) by 567.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 180,800 shares of the biotechnology company’s stock after acquiring an additional 153,700 shares during the period. Canada Pension Plan Investment Board owned 0.41% of United Therapeutics worth $41,533,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Rise Advisors LLC acquired a new position in shares of United Therapeutics in the 1st quarter valued at $32,000. GAMMA Investing LLC purchased a new position in shares of United Therapeutics during the 4th quarter valued at about $43,000. Benjamin F. Edwards & Company Inc. raised its stake in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 117 shares during the last quarter. Janiczek Wealth Management LLC raised its stake in shares of United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 84 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in shares of United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 46 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $235.35, for a total transaction of $847,260.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,595.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $235.35, for a total transaction of $847,260.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,595.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Nilda Mesa sold 266 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total value of $84,742.28. Following the completion of the transaction, the director now owns 5,107 shares in the company, valued at $1,626,988.06. The disclosure for this sale can be found here. Insiders have sold a total of 100,884 shares of company stock worth $29,622,803 in the last ninety days. Insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of a number of recent research reports. JPMorgan Chase & Co. lifted their price objective on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, May 21st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 15th. Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. HC Wainwright lifted their price target on United Therapeutics from $300.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday. Finally, The Goldman Sachs Group lifted their price target on United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $330.64.

United Therapeutics Trading Up 0.5 %

UTHR stock opened at $338.22 on Friday. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $343.98. The stock has a market cap of $15.00 billion, a price-to-earnings ratio of 15.99, a PEG ratio of 1.48 and a beta of 0.55. The business’s 50-day moving average is $303.01 and its 200 day moving average is $257.47.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping the consensus estimate of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.86 EPS. On average, sell-side analysts anticipate that United Therapeutics Co. will post 24.94 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.